Last reviewed · How we verify
Physician's choice chemotherapy
Physician's choice chemotherapy is a Chemotherapy Small molecule drug developed by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. It is currently in Phase 3 development for Metastatic breast cancer, Metastatic colorectal cancer, Metastatic non-small cell lung cancer. Also known as: Albumin-bound paclitaxel injection, Pemetrexed disodium for injection, Gemcitabine for injection, no other name.
Physician's choice chemotherapy involves administering a selection of chemotherapy drugs tailored to the individual patient's needs.
Physician's choice chemotherapy involves administering a selection of chemotherapy drugs tailored to the individual patient's needs. Used for Metastatic breast cancer, Metastatic colorectal cancer, Metastatic non-small cell lung cancer.
At a glance
| Generic name | Physician's choice chemotherapy |
|---|---|
| Also known as | Albumin-bound paclitaxel injection, Pemetrexed disodium for injection, Gemcitabine for injection, no other name |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Drug class | Chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The choice of chemotherapy drugs is based on the type and stage of cancer, as well as the patient's overall health. This approach allows for a more personalized treatment plan, which can be adjusted as needed.
Approved indications
- Metastatic breast cancer
- Metastatic colorectal cancer
- Metastatic non-small cell lung cancer
- Metastatic ovarian cancer
- Metastatic pancreatic cancer
- Metastatic prostate cancer
- Metastatic stomach cancer
Common side effects
- Nausea
- Vomiting
- Fatigue
- Hair loss
- Diarrhea
- Anemia
- Neutropenia
Key clinical trials
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (PHASE3)
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (PHASE3)
- Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial (PHASE3)
- Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (PHASE2)
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) (PHASE3)
- Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Physician's choice chemotherapy CI brief — competitive landscape report
- Physician's choice chemotherapy updates RSS · CI watch RSS
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University portfolio CI
Frequently asked questions about Physician's choice chemotherapy
What is Physician's choice chemotherapy?
How does Physician's choice chemotherapy work?
What is Physician's choice chemotherapy used for?
Who makes Physician's choice chemotherapy?
Is Physician's choice chemotherapy also known as anything else?
What drug class is Physician's choice chemotherapy in?
What development phase is Physician's choice chemotherapy in?
What are the side effects of Physician's choice chemotherapy?
Related
- Drug class: All Chemotherapy drugs
- Manufacturer: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic breast cancer
- Indication: Drugs for Metastatic colorectal cancer
- Indication: Drugs for Metastatic non-small cell lung cancer
- Also known as: Albumin-bound paclitaxel injection, Pemetrexed disodium for injection, Gemcitabine for injection, no other name
- Compare: Physician's choice chemotherapy vs similar drugs
- Pricing: Physician's choice chemotherapy cost, discount & access